HC Wainwright Brokers Lower Earnings Estimates for BioCardia

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright reduced their Q2 2026 earnings estimates for BioCardia in a research note issued to investors on Tuesday, June 9th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.19) per share for the quarter, down from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for BioCardia’s Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.42) EPS.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04).

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.00.

BioCardia Stock Performance

Shares of NASDAQ:BCDA opened at $0.81 on Thursday. The company has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.21. BioCardia has a one year low of $0.81 and a one year high of $2.45. The stock has a market capitalization of $9.22 million, a price-to-earnings ratio of -0.89 and a beta of 0.51.

Institutional Trading of BioCardia

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its position in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares during the last quarter. DRW Securities LLC acquired a new stake in BioCardia during the fourth quarter worth approximately $72,000. Finally, Cetera Investment Advisers acquired a new stake in BioCardia during the second quarter worth approximately $40,000. 20.57% of the stock is currently owned by institutional investors and hedge funds.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.